WO2015049633A1 - FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. - Google Patents
FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. Download PDFInfo
- Publication number
- WO2015049633A1 WO2015049633A1 PCT/IB2014/064963 IB2014064963W WO2015049633A1 WO 2015049633 A1 WO2015049633 A1 WO 2015049633A1 IB 2014064963 W IB2014064963 W IB 2014064963W WO 2015049633 A1 WO2015049633 A1 WO 2015049633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hmpv
- protein
- immunogenic
- clause
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000009472 formulation Methods 0.000 title claims abstract description 63
- 230000002163 immunogen Effects 0.000 title claims abstract description 60
- 241000351643 Metapneumovirus Species 0.000 title claims description 11
- 239000002671 adjuvant Substances 0.000 title abstract description 9
- 239000000427 antigen Substances 0.000 title description 3
- 102000036639 antigens Human genes 0.000 title description 3
- 108091007433 antigens Proteins 0.000 title description 3
- 239000000725 suspension Substances 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 21
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 9
- 238000004108 freeze drying Methods 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 63
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 101710177166 Phosphoprotein Proteins 0.000 claims description 43
- 208000015181 infectious disease Diseases 0.000 claims description 41
- 101710181008 P protein Proteins 0.000 claims description 36
- 102100034574 P protein Human genes 0.000 claims description 35
- 241000894006 Bacteria Species 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 20
- 241000186359 Mycobacterium Species 0.000 claims description 18
- 230000002238 attenuated effect Effects 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 108050001049 Extracellular proteins Proteins 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 241000342334 Human metapneumovirus Species 0.000 abstract description 108
- 101150084044 P gene Proteins 0.000 abstract description 12
- 230000036961 partial effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 27
- 241000700605 Viruses Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000008595 infiltration Effects 0.000 description 15
- 238000001764 infiltration Methods 0.000 description 15
- 239000013598 vector Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 241000711920 Human orthopneumovirus Species 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000035874 hyperreactivity Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229920001664 tyloxapol Polymers 0.000 description 5
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 5
- 229960004224 tyloxapol Drugs 0.000 description 5
- 102000006303 Chaperonin 60 Human genes 0.000 description 4
- 108010058432 Chaperonin 60 Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000701867 Enterobacteria phage T7 Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 4
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 4
- 102100024407 Jouberin Human genes 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229960004642 ferric ammonium citrate Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000004313 iron ammonium citrate Substances 0.000 description 4
- 235000000011 iron ammonium citrate Nutrition 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 101150103632 M2-2 gene Proteins 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000144290 Sigmodon hispidus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150109930 ACR gene Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101150023414 HSP60 gene Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 101150039699 M2-1 gene Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 239000001971 Middlebrook 7H10 Agar Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to the areas of immunology and biotechnology, specifically addressing an immunogenic formulation based on a recombinant attenuated bacterium to be used in the preparation of a vaccine against human Metapneumo virus (hMPV).
- This formulation contains the recombinant Calmette and Guérin Bacillus (BCG), which expresses the antigenic peptide protein P of the hMPV virus.
- BCG Calmette and Guérin Bacillus
- the human Metapneumo virus (hereinafter hMPV), is the etiologic agent of a high percentage of hospitalizations and morbidity associated with acute respiratory diseases of the upper and lower respiratory tracts, especially in infants, the elderly and individuals immunocompromised. Infection with this virus is associated with a wide range of pathologies, within which bronchiolitis and pneumonia correspond to the cases with the greatest socio-economic impact. Additionally, they have been associated with gastroenteritis, and keratoconjunctivitis. Calvo et al.
- the hMPV virus is classified in the family Paramyxoviridae subfamily Pneumovirinae, the same in which hRSV is classified, although each is grouped into the genera Metapneumo virus and Pneumovirus, respectively.
- the hMPV genome is composed of single stranded non-segmented ribonucleic acid (ssRNA), so viral proteins are organized in a 3 'to 5' direction (with respect to their sequence) as follows: N, P, M, F, M2 (ORF1 and 2), SH, G and L.
- the other proteins are responsible for packing the genetic material and defining the structure of the viral particle, corresponding to the nucleocapsid protein N and the M matrix protein, together with transmembrane glycoproteins F, G and SH, respectively.
- the other four proteins, M2-1, M2-2, P and L, are involved in viral replication and transcription.
- hRSV-FI formalin inactivated virus
- hMPV-FI formalin inactivated virus
- the increase in NF- ⁇ transcriptional activity is further related to the secretion of pro-inflammatory cytokines such as IL-8.
- pro-inflammatory cytokines such as IL-8.
- the hyper-reactivity of the lung tissue after hMPV infection has been associated with immune responses characterized by the presence of IFN- ⁇ and IL-4 in broncho-alveolar lavage and the detection of neutralizing antibodies of the IgGl isotypes. and serum IgG2a from diseased mice, strongly suggesting that the chronic inflammation observed is due to pathological responses of the Thl and Th2 types, or to an insufficient response based on Thl type cells that is accompanied by a Th2 pathological response.
- some authors have proposed that an increased response of the Thl type could also exacerbate the disease.
- hVRS For hVRS, some of them have been based on the use of individual viral proteins, such as complete subunits or fragments, of F or G proteins, or a mixture of them in models of murine infection and nonhuman primates. Some prototypes of hVRS vaccine have been used in phase I and II clinical trials, but the results have not demonstrated a long-term protective capacity, and the vaccines are far from being suitable for mass use in infection prophylaxis (Denis et al., 2005; Karron et al., 2005).
- Antibodies capable of neutralizing hMPV in vitro are not able to prevent infection or disease caused by hMPV, when used as therapies by passive immunization (Hamelin et al., 2008).
- the resolution of the viral condition requires the participation of a cell-based immune response, of the Thl type. It was shown that the resolution of the viral picture and the removal of viral particles is dependent on the activation of CD4 + and CD8 + lymphocytes, although their activity is also responsible for the immunopathology of the disease (Kolli et al., 2008).
- the inventors have found that the use of a recombinant strain of Mycobacterium that expresses the P protein of the human Metapneumo virus allows generating a protective immunity against infection by the respiratory virus Metapneumovirus, without causing unacceptable side effects, such as hyper-inflammatory reactivity The airways.
- This invention solves a technical problem that remained unresolved in the prior art, which consists of an immunogenic formulation that provides protection against hMPV infections and does not generate hyper inflammatory reactivity.
- Figure 1 Generation of construction pMV361-P-hMPV. From the metapneumovirus RNA, reverse transcription was performed with universal splitters and subsequently amplified with the P-hMPV-Fw and P-hMPV-Rv splitters of the open reading frame of the P gene. Sites were incorporated into the amplification product. EcoRI at both ends and inserted into the EcoRI site of the mycobacterial vector pMV361 to generate the construction of the vector pMV361-P-hMPV.
- Figure 1A shows the hMPV genome, and the gene encoding the P protein
- Figure IB shows the vector pMV361-P-hMPV incorporating said gene encoding the P protein.
- FIG. 1 Expression of the P protein or M2.1 protein of hMPV by recombinant strains of Mycobacterium BCG.
- the Danish strain of Mycobacterium BCG was electrotransformed with plasmid pMV361-P-hMPV and Middlebrook 7H10 agar medium supplemented with oleic acid, albumin, dextrose and catalase containing 20 ⁇ g / ml kanamycin was selected. It has been made an SDS-PAGE (CB) electrophoresis and a Western Blot (WB), using hMPV anti-protein P monoclonal antibodies (WB).
- CB SDS-PAGE
- WB Western Blot
- Figure 2A western blot, using hMPV protein P monoclonal antibodies
- Figure 2B western blot, using hMPV M2.1 protein monoclonal antibodies.
- SDS-PAGE 25 ⁇ g of total protein prepared from four clones of rBCG-P-hMPV ( Figure 2A) or five clones of rBCG-M2.1-hMPV ( Figure 2B) was loaded.
- As a positive control 5 ng of recombinant P-hMPV protein or 25 ⁇ g of inactivated hMPV were loaded as appropriate.
- FIG. 3 Immunization with recombinant rBCG-P-hMPV protects against infection with hMPV.
- CFU colony forming units
- rBCG-P-hMPV or BCG-WT (wild) 6 plaque-forming units (UFP) of live virus (Live-hMPV) or UV-inactivated virus (UV-hMPV) were also vaccinated with lxlO
- Control groups included unvaccinated animals and another group of uninfected animals. During the six days after infection, the weight of the animals was recorded and they were sacrificed at the end of the experiment and from each one the alveolar bronchial lavage (BAL) and lung was obtained. The symbols represent each individual animal and the horizontal bar is the average.
- Figure 3 A Graph of weight loss by group of animals after infection.
- Figure 3 B Total cells that infiltrate the airways.
- Figure 3 C Percentage of cells that give a positive reaction to double staining for CDl lb and Grl in the BAL.
- Figure 3 D Determination of hMPV RNA in the lung of infected mice, by quantitative PCR.
- Figure 3D shows that the number of hMPV viruses expressed in copies of the N-hMPV gene per 5000 copies of ⁇ -actin, present in the lungs of non-immunized infected animals is similar to that of infected animals immunized with BCG-WT, Live-hMPV or UV-hMPV, that is, would not grant protection, while infected animals immunized with rBCG-P-MPV virtually no virus is found, as in uninfected animals. Immunization with rBCG-M2 granted non-complete protection.
- FIG. 4 Immunization with rBCG-P-hMPV protects against inflammation after challenge with hMPV.
- Significant infiltration of nuclear polymorphic cells is observed in animals not immunized or immunized with rBCG-M2.1-hMPV or BCG-WT.
- the images are representative of six independent experiments.
- HSP represents the quantification of an inflammation score by group of animals (Histopathology Score). It can be seen that the inflammation in animals immunized with rBCG-P-MPV and infected was very low or non-existent, similar to that seen in non-infected animals.
- rBCG-P-hMPV-P- cytokine profile of BALB / cj spleen cells immunized with the recombinant BCG strain for hMPV P protein
- rBCG-P- hMPV P protein
- the spleen was recovered from four BALB / cj mice immunized with rBCG-P-hMPV and the spleen cells were stimulated for 7 days by incubation with 10 ⁇ g of P-hMPV protein or PBS (in the I / O graphics).
- BALB / cj spleen cells immunized with BCG-WT were cultured under the same conditions.
- the supernatant of the stimulated and unstimulated rBCG-P-hMPV and BCG-WT spleen cells were determined by ELISA levels of (A) IFN- ⁇ , (B) IL-2, (C) IL-5 and (D) IL-4 on days 4 and 7 of culture.
- Spleen cells derived from rBCG-P-hMPV stimulated with P-hMPV protein secrete significantly larger amounts of IFN- ⁇ compared to cells from animals immunized with BCG-WT or unstimulated cells (rBCG-P U / S) (*** p ⁇ 0.001, Student's t-test), Figure 5 A.
- the amounts of IFN- ⁇ increased between day 4 to 7 (* p ⁇ 0.05, Student's t-test) , Figure 5 A.
- FIG. 6 Transfer of T lymphocytes of mice immunized with rBCG-P-hMPV confer resistance to hMPV infection in mice na 'ive.
- CD4 + T lymphocytes and CD8 + T lymphocytes were purified from splenocytes stimulated and not stimulated with recombinant viral proteins.
- mice transferred with CD4 + and / or CD8 + T cells from mice immunized with rBCG-P-hMPV show no difference in body weight compared to uninfected mice.
- mice transferred with CD4 + and / or CD8 + T lymphocytes from mice immunized with BCG-WT lost significantly more weight after infection, compared to non-infected animals (p ⁇ 0.0001) ( Figure 6B).
- Figure 6C shows that in the alveolar bronchus wash, BAL, of nai ' ve mice previously transferred with CD4 + and / or CD8 + T cells from mice immunized with rBCG-P-hMPV (P-CD8, P-CD4, P- CD8 / 4), show significantly less granulocyte infiltration compared to mice transferred with BCG-WT T lymphocytes (Wt-CD8, Wt-CD4, Wt-CD8 / 4) (*** p «3,0001, test Student's t).
- the viral load was quantified as gene copies of N-hMPV by RT-qPCR, as described above.
- the present invention consists of an immunogenic formulation against hMPV comprising a recombinant BCG strain that expresses the P protein of the human Metapneumo virus. This formulation provides effective protection against hMPV infections and does not generate a response of inflammatory hyper reactivity.
- the formulation of the invention can be supplied alone or mixed with other vaccines, such as with an immunogenic formulation against RSV, in a mixed dose that would provide protection against infection and / or complications associated with hMPV and RSV.
- Detailed immunogenic formulation in this invention can be used to prepare vaccines containing attenuated live axenic cultures from recombinant bacteria in doses between lxlO 4 cfu to 10 cfu per dose lxlO, especially dose of 1x10 s cfu per dose are preferred.
- the formulation will be lyophilized with a restorative solution that does not need adjuvant, since the composition of the cell envelope of the recombinant bacterium is the adjuvant.
- the lyophilized immunogenic formulation of the invention should be stored between 4 and 8 o C, protected from direct and indirect sunlight, in the presence of two separate bottles, one with the lyophilized recombinant bacteria, and another with the reconstituting saline solution, to be mixed previously to his administration. Since its introduction in 1921, the Mycobacterium bovis bacillus Calmette-Guerin (BCG) -based vaccine has been used in more than one billion people and is currently used around the world against tuberculosis.
- BCG Mycobacterium bovis bacillus Calmette-Guerin
- the inventors have found that a way to shift the balance of the immune response from a pro-inflammatory Th2 type response whose protection is not lasting over time towards a cell-based Thl response, specifically cytotoxic CD8 + T cells and T cells CD4 + helper is to use adjuvants as the components of the cell wall of Mycobacterium. Specifically, express hMPV immunogenic protein in Mycobacterium bovis bacillus Calmette-Guerin (BCG).
- BCG Mycobacterium bovis bacillus Calmette-Guerin
- the F and G proteins of hPMV are found on the surface of the viral particle and are therefore accessible to circulating antibodies. For this reason, these proteins would be the most obvious choice to make a vaccine based on the production of antibodies to prevent hMPV infection.
- capsid proteins specifically P protein
- an adjuvant that promotes a response based on Thl type cells, such as the attenuated bacteria Mycobacterium bovis BCG .
- capsid proteins like M2.1 of hMPV promote the activation of cytotoxic lymphocytes (LTC).
- LTC cytotoxic lymphocytes
- the recombinant proteins expressed by the vector bacterium used in this invention are obtained by cloning the genes encoding them from hMPV group A virus into prokaryotic expression vectors, all commercially available.
- the genome of Metapneumo virus (hMPV) has been described previously and is available in the GeneBank databases, access number: AB503857.1, DQ843659.1, DQ843658.1, EF535506.1, GQ153651.1, AY297749 .1, AY297748.1, AF371337.2, FJ168779.1, FJ168778.1, NC_004148.2 and AY525843.1.
- hMPV proteins can be genetically modified, such as by incorporating peptide sequences or glycosylation domains and / or subsequent destination to endocytic or phagocytic receptors of antigen presenting cells, by coupling to natural ligands through the use of the system.
- biotin-streptavidin using commercial biotinylation kits and genetic modification of viral proteins by coupling to the bacterial streptavidin protein, or by introducing the genetic sequence coding for amino acid sequences described as biotinylation signals in proteins or fragments recombinant proteins, using techniques previously described for heterologous prokaryotic and / or eukaryotic expression systems).
- the immunogenic formulation of the invention comprises the expression of the hMPV P protein either complete or an immunogenic fragment thereof, in an attenuated strain of Mycobacterium.
- the attenuated recombinant Mycobacterium strain is derived from the Bacillus Calmette-Guerin (BCG) strain.
- BCG Bacillus Calmette-Guerin
- the hMPV P protein may correspond to the P protein of Metapneumo virus of subtypes A or B.
- the recombinant Mycobacterium attenuated strain of the invention may contain the nucleic acid sequences encoding the hMPV P protein or its immunogenic fragment inserted in the bacterial genome or in an extrachromosomal plasmid, in one or more copies. Protein expression may be under the control of constitutive or inducible, endogenous or exogenous promoters of Mycobacterium BCG.
- the hMPV P protein or its immunogenic fragment can be expressed in soluble, soluble-cytoplasmic form, as secreted extracellular protein, or membrane bound.
- the immunogenic formulation of the invention may comprise two or more recombinant attenuated Mycobacterium strains, and wherein the hMPV P protein immunogenic proteins or fragments of the strains are expressed to generate a different number of copies, constitutively or induciblely expressed, and / or are located in different cell locations.
- the immunogenic formulation disclosed in the present invention can be used in conjunction with immunogenic formulations containing other antigenic formulations against viruses other than hVRS and hMPV, with attenuated strains of BCG and seasonal vaccines against influenza A and B.
- the immunogenic formulation described above can be applied to the individual subcutaneously / subdermally in conjunction with a saline buffer (PBS, sodium phosphate buffer) or physiological solution.
- a saline buffer PBS, sodium phosphate buffer
- a vector that expresses said protein must first be generated. Any known mycobacterial expression vector can be used, and the gene encoding the hMPV virus P protein in phase with its promoter region must be inserted. In a preferred embodiment, reverse transcription is performed with universal cleaners from the isolated human virus metapneumo RNA. Subsequently, the P protein gene is amplified with specific splitters ( Figure 1A). The amplification product is inserted into the expression vector. In the present invention, the mycobacterial expression vector pMV361 has been used, generating the vector pMV361 -P-hMPV ( Figure IB).
- the vector is used to transform the Mycobacterium strain, such as Mycobacterium BCG.
- Mycobacterium BCG Any known BCG strain, such as BCG Danish or BCG Pasteur, can be used for the purposes of the invention.
- the transformation method can be any available method, especially electrotransformation is preferred. Subsequently, the transformed cells expressing hMPV P protein must be selected.
- These recombinant cells constitute the immunogenic formulation of the invention, which is provided in amounts of between 10 4 to 10 9 CFU / dose in a pharmacologically acceptable saline buffer.
- the formulation of the invention can be formulated in combination with recombinant BCG strains that express immunogenic syncytial virus (RSV) proteins.
- RSV immunogenic syncytial virus
- the BCG recombinant bacterium that expresses the hMPV P protein is provided in conjunction with BCG recombinant bacteria that express N, P, M, F, M2 (ORF1 and 2), SH, G or L RSV proteins.
- the formulation Immunogenic of the invention is used in combination with a recombinant BCG strain for the RSV N gene.
- a strain of BCG is transformed with a vector that expresses the hMPV P protein and subsequently the transformed cell is transformed again with a vector that expresses a syncytial virus protein (RSV).
- the RSV protein is chosen from N, P, M, F, M2 (ORF1 and 2), SH, G or L. It is especially preferred to first transform with a vector that expresses the P protein of hMPV subtype A, and in Secondly, subject these transformed strains to a second transformation with a vector that expresses the N gene of RSV subtype A, obtaining a BCG strain that simultaneously expresses the P proteins of hMPV subtype A and N of RSV subtype A.
- the immunogenic formulation of the invention can be provided lyophilized in a multidose presentation ready to be reconstituted in 1 ml of an attached saline solution, to obtain a solution of 9 ug / ml of reconstituted solution.
- Each 0.1 ml of resuspended solution will contain the appropriate dose of 1x10 s for the administration.
- the transformed strains of the invention can be suspended in any appropriate lyophilization solution, for example, the LYO C buffer, composed of 4% mannitol (w / v), 0.05% Tyloxapol (w / v), 0.25% sucrose and 5 mM histidine. to then be lyophilized and preserved at 25 ° C.
- the LYO C buffer composed of 4% mannitol (w / v), 0.05% Tyloxapol (w / v), 0.25% sucrose and 5 mM histidine.
- the reconstituting solution can be any solution available in the art, in one embodiment a dilute solution Sauton SSI (125 mg MgS0 4, K 2 HP0 125 mg 4 1 mg L-asparagine, 12.5 g ferric ammonium citrate is preferred, 18.4 mg 85% glycerol, 0.5 mg citric acid in 1 ml of H20) at -80 ° C.
- Sauton SSI 125 mg MgS0 4, K 2 HP0 125 mg 4 1 mg L-asparagine, 12.5 g ferric ammonium citrate is preferred, 18.4 mg 85% glycerol, 0.5 mg citric acid in 1 ml of H20) at -80 ° C.
- the formulation of the invention can be suspended in a solution of PBS (137 mM NaCl; 2.7 mM KC1; 4.3 mM Na2HP04; 1.47 mM KH2P04, pH 7.4), supplemented with 20% Glycerol and Tween 80 0.02% at a final concentration of 10 8 bacteria per 100 ⁇ and stored at -80 ° C. Both in the presence of a non-ionic detergent such as 0.1% Tween®-80 or 0.05% Tyloxapol.
- the formulation of the invention should be kept between 4 to 8 ° C, before and after reconstitution, at all times away from direct and indirect sunlight and once reconstituted should be removed at the end of the day.
- the following examples of the generation and use of the immunogenic formulation against hMPV based on the recombinant bacterium Mycobacterium expressing viral proteins are only illustrative and are not intended to limit the range of production or application of the invention. Although specific terms are used in the following descriptions, their use is only descriptive and not limiting.
- Example I Generation of a recombinant vector allows the expression of the P protein of hMPV in the Mycobacterium BCG bacteria.
- the coding region of the P gene was amplified using the following splitters: P-hMPV_Fw: GAATTCATGTCATTCCCTGAAGGAAA (SEQ ID No 1) and P-hMPV_Rv: GAATTCCTACATAATTAACTGGTAAA (SEQ ID No 2), where the underlined sequences incorporate EcoRI site at both ends of the amplification product, Figure 1A.
- the mycobacterial vector pMV361 was linearized at the EcoRI site, which allowed the insertion of the following sequence corresponding to the P gene of hMPV:
- Example II Immunogenic formulation consisting of 10 doses of lxlO 8 CFU each of the recombinant BCG Danish strain for the P gene of hMPV subtype A.
- the P gene of hMPV subtype A is inserted into a copy in the genome of the bacterium under the regulation of the constitutive endogenous promoter hsp60 of Mycobacterium BCG for protein expression.
- the Mycobacterium BCG Danish strain (ATCC 35733) was transformed by electrotransformation with plasmid pMV361-P-hMPV, derived from plasmid pMV361 (Stover et al., 1991), which is inserted only once into the genome of the bacterium.
- This plasmid contains the gene that codes for hMPV protein P subtype A, which is expressed under the endogenous promoter and constitutive of the hsp60 BCG gene.
- PBS solution 137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4
- strains can be resuspended in a solution volume: 25% lactose volume and Proskauer and Beck medium supplemented with glucose and Tween 80 (PBGT: 0.5 g asparagine; 5.0 g monopotassium phosphate; 1.5 g citrate magnesium; 0.5 g potassium sulfate; 0.5 ml Tween 80 and 10.0 g glucose per liter of distilled water) and then freeze-dried and stored at 25 ° C.
- PBGT glucose and Tween 80
- RNA copies of the N-hMPV gene in the lung cells of the different groups studied was analyzed. A larger number of RNA copies of the hMPV virus is indicative of a higher infection, the results are normalized by copies of ⁇ -actin. The results are shown in Figure 3D. It is appreciated that the number of hMPV viruses present in the lungs of non-immunized infected animals is similar to that of infected animals immunized with BCG-WT, Live-hMPV or UV-hMPV, that is, these immunizations would not grant protection. It is noted that immunization with rBCG-M2 granted a non-complete protection.
- Example III Immunogenic formulation consisting of 5xl0 7 bacteria of the recombinant Mycobacterium BCG Danish strain for the P gene of hMPV subtype A and 5xl0 7 bacteria of the recombinant Mycobacterium BCG Danish strain for the N gene of RSV subtype A.
- the hMPV and RSV genes are inserted in a copy in the genome of the bacteria under the regulation of the constitutive endogenous promoter hsp60 of BCG and the expression of the protein is cytoplasmic.
- the immunogenic formulation is preserved in PBS (137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4), supplemented with 20% Glycerol and Tween 80 0.02% at a final concentration of 10 8 bacteria per 100 ⁇ and stored at -20 ° C.
- BCG Danish strains (ATCC 35733) were transformed by electrotransformation with the plasmid pMV361-P from hMPV to give the strain of the invention rBCG-P-MPV, and additionally a second group was transformed with pMV361-N from VRS to obtain the transformed strain rBCG-N VRS, these plasmids are derived from plasmid pMV361 (Stover et al., 1991), which are inserted only once into the genome of the bacterium.
- a strain of BCG Danish was transformed with the P gene of hMPV subtype A, so that the gene was inserted into a copy in the genome of the bacterium under the regulation of the BCG inducible endogenous promoter, which is active in response to nitric oxide, low oxygen concentrations, and stationary phases of growth. Protein expression is cytoplasmic.
- the immunogenic formulation was lyophilized in LYO C buffer, composed of 4% mannitol (w / v), 0.05% tyloxapol (w / v), 0.25% sucrose and 5 mM histidine and conserved 25 ° reconstituted C in diluted solution Sauton SSI (125 ⁇ g MgS0 4 , 125 ⁇ g K 2 HP0 4 , 1 mg L-asparagine, 12.5 ⁇ g ferric ammonium citrate, 18.4 mg 85% glycerol, 0.5 mg citric acid in 1 mi from H 2 0).
- LYO C buffer composed of 4% mannitol (w / v), 0.05% tyloxapol (w / v), 0.25% sucrose and 5 mM histidine and conserved 25 ° reconstituted C in diluted solution Sauton SSI (125 ⁇ g MgS0 4 , 125 ⁇ g K 2 HP0 4 , 1 mg L-
- the transformed strains can be preserved in a PBS solution (137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4) supplemented with Tween 80 0, 02% and 20% glycerol at a final concentration of 10 4 bacteria per 100 ⁇ .
- PBS solution 137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4
- the BCG Danish strain (American Type Culture Collection, www.atcc.org, ATCC number 35733) was transformed by electrotransformation with plasmid pMV361p ac / P-hMPV, derived from plasmid pMV361 (Stover et al., 1991), which is inserted only once in the genome of the bacteria.
- This plasmid contains the gene encoding the hMPV protein P subtype A, which is expressed under the endogenous and inducible promoter of the BCG acr gene.
- ODóoo nm 1, centrifuged at 4,000 rpm for 20 min (eppendorf rotor model 5702 / R A-4-38) and resuspended in a LYO C buffer solution, composed of 4% mannitol (w / v), 0.05% Tyloxapol (w / v), 0.25% sucrose and 5 mM histidine. Finally, 1 ml aliquots were lyophilized with 10 4 bacteria and stored at 25 ° C.
- the strains can be preserved in a PBS solution (137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4) supplemented with Tween 80 0.02% and Glycerol 20% at a final concentration of 10 4 bacteria per 100 ⁇ .
- This immunogenic formulation confers immunity against the hMPV virus.
- Example V Immunogenic formulation consisting of 10 9 bacteria of recombinant BCG Danish strain for the P gene of hMPV subtype A.
- the gene is inserted in a copy in the genome of the bacteria under the regulation of the exogenous promoter of phage T7 constitutive expression in BCG strains that co-express polymerase of phage T7. Protein expression is cytoplasmic.
- the immunogenic formulation is in a diluted Sauton SSI solution (125 ⁇ g MgS0 4 , 125 ⁇ g K 2 HP0 4 , 1 mg L-asparagine, 12.5 ⁇ g ferric ammonium citrate, 18.4 mg 85% glycerol, 0.5 mg citric acid in 1 ml of H 2 0) and was stored at -20 ° C, or it may be freeze-dried and stored at 4 ° C.
- the strains can be preserved in a PBS solution (137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4) supplemented with Tween 80 0.02% and Glycerol 20% at a final concentration of 10 9 bacteria per 100 ⁇ .
- PBS solution 137 mM NaCl; 2.7 mM KC1; 4.3 mM Na 2 HP0 4 ; 1.47 mM KH 2 P0 4 , pH 7.4
- the BCG Danish ATCC 35733 strain was transformed by electrotransformation with plasmid pMV361pT7 / P-hMPV, derived from plasmid pMV361 (Stover et al., 1991), which is inserted only once into the genome of the bacterium.
- This plasmid contains the gene that codes for hMPV protein P subtype A, which is expressed under the T7 promoter activated by expression of phage T7 polymerase.
- the resulting BCG strain was transformed by electrotransformation with plasmid pMV26lAm P / PolT7, derived from plasmid pMV261 (Stover et al., 1991), which resides extrachromosomally in the bacterium in multiple copies.
- plasmid pMV26lAm P / PolT7 derived from plasmid pMV261 (Stover et al., 1991), which resides extrachromosomally in the bacterium in multiple copies.
- the resistance to the antibiotic kanamycin has been replaced by the resistance to the antibiotic hygromycin (Higr).
- the T7 polymerase of phage T7 is under the control of the constitutive promoter of the hsp60 gene of BCG.
- the inoculation of the formulation in any of its presentations also significantly decreases the histopathological manifestations of infection by strains A and B of hMPV.
- the lungs of animals vaccinated with the formulation demonstrate much less infiltration of immune cells, loss of structure and inflammation of the lung tissues compared to animals not immunized or immunized with the wild type strain ( Figure 4).
- Inoculation of the formulation with recombinant BCG expressing the P protein of hMPV in any presentation generates based immunity cells can be transferred to nai individuals' seen by the recovery and purification of T cells from donors immunized individuals ( Figure 6 ).
- the examples are extended to immunological formulations containing one or more attenuated recombinant Mycobacterium strains; where said recombinant bacteria contain protein genes, or immunogenic fragments of the hMPV P protein that are inserted either in the bacterial genome or in extrachromosomal plasmids, in one or several copies, and their expression is commanded by endogenous or exogenous promoters, constitutive or inducible, expressed, soluble-cytoplasmic, secreted extracellularly or as proteins bound to the cell membrane.
- T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection. J Virol 82, 8560-8569.
- Human metapneumovirus enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 25, 5034-5040.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2925369A CA2925369C (en) | 2013-10-01 | 2014-09-30 | Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use |
DE112014004530.6T DE112014004530T5 (de) | 2013-10-01 | 2014-09-30 | Immunogene Formulierung enthaltend einen rekombinanten lebenden BCG, welche Antigene von Metapneumovirus (HMPV) exprimiert, in einer aus einem Lyophilisat zubereiteten Suspension, ohne einen Hilfsstoff zu benötigen, welche geeignet für deren pharmazeutischen Verwendung ist |
US15/025,976 US9999663B2 (en) | 2013-10-01 | 2014-09-30 | Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use |
RU2016111978A RU2665848C2 (ru) | 2013-10-01 | 2014-09-30 | Иммуногенная лекарственная композиция для медицинского использования, содержащая рекомбинант живой бцж, выделяющий антигены метапневмовируса (hmpv) в суспензию, приготовленную из лиофилизата без добавления адъюванта |
ES14850538T ES2853355T3 (es) | 2013-10-01 | 2014-09-30 | Formulación inmunogénica que contiene BCG vivas recombinantes que expresan antígenos de Metapneumovirus (hMPV), en una suspensión que se prepara a partir de un liofilizado sin la necesidad de adyuvante, apta para su uso farmacéutico |
GB1605054.4A GB2532699B (en) | 2013-10-01 | 2014-09-30 | Immunogenic Formulation Comprising Live BCG Expressing hMPV P Proteins |
MX2016003783A MX2016003783A (es) | 2013-10-01 | 2014-09-30 | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv), en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante, apta para su uso farmaceutico. |
EP14850538.1A EP3054013B1 (en) | 2013-10-01 | 2014-09-30 | Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use |
BR112016006989-7A BR112016006989B1 (pt) | 2013-10-01 | 2014-09-30 | Formulação imunogênica, uso de uma formulação imunogênica e vacina contra hmpv |
KR1020167011372A KR101822836B1 (ko) | 2013-10-01 | 2014-09-30 | 약제학적 사용에 적합한, 보조제를 요구하지 않는, 동결건조물로부터 준비된 현탁액 내의 메타뉴모바이러스 (hmpv)의 항원을 발현하는 재조합 생 bcg를 함유하는, 면역원성 제제 |
CN201480060545.XA CN105745323B (zh) | 2013-10-01 | 2014-09-30 | 包含表达偏肺病毒(hMPV)抗原的重组活BCG的免疫原性制剂,其以无需佐剂地从冻干物制备的悬浮液形式存在并且适合于其制药用途 |
ZA2016/02148A ZA201602148B (en) | 2013-10-01 | 2016-03-31 | Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CLCL2013-02829 | 2013-10-01 | ||
CL2013002829A CL2013002829A1 (es) | 2013-10-01 | 2013-10-01 | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015049633A1 true WO2015049633A1 (es) | 2015-04-09 |
Family
ID=52778317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/064963 WO2015049633A1 (es) | 2013-10-01 | 2014-09-30 | FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9999663B2 (es) |
EP (1) | EP3054013B1 (es) |
KR (1) | KR101822836B1 (es) |
CN (1) | CN105745323B (es) |
AR (1) | AR097881A1 (es) |
BR (1) | BR112016006989B1 (es) |
CA (1) | CA2925369C (es) |
CL (1) | CL2013002829A1 (es) |
DE (1) | DE112014004530T5 (es) |
ES (1) | ES2853355T3 (es) |
GB (1) | GB2532699B (es) |
MX (1) | MX2016003783A (es) |
PE (1) | PE20160536A1 (es) |
RU (1) | RU2665848C2 (es) |
UY (1) | UY35765A (es) |
WO (1) | WO2015049633A1 (es) |
ZA (1) | ZA201602148B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
EP4268846A1 (en) * | 2020-12-23 | 2023-11-01 | Pontificia Universidad Católica De Chile | Immunogenic formulation containing one or more modified bcg strains expressing a sars-cov-2 protein, useful for preventing, treating or attenuating the development of covid-19 |
CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007120120A2 (en) * | 2005-01-12 | 2007-10-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human parainfluenza virus, methods and uses thereof |
WO2008137981A1 (en) * | 2007-05-08 | 2008-11-13 | Us Government As Represented By The Secy Of The Department Of Health And Human Services | Human parainfluenza viruses having separated p and c genes |
ES2393468T3 (es) * | 2001-01-19 | 2012-12-21 | Vironovative B.V. | Un virus que provoca enfermedad de las vías respiratorias en mamíferos susceptibles |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072720A2 (en) * | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
WO2005027825A2 (en) | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
CL2007002710A1 (es) * | 2007-09-20 | 2008-01-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
GB0809881D0 (en) * | 2008-05-30 | 2008-07-09 | Genomica Sau | Method for detecting respiratory viral agents in a test sample |
-
2013
- 2013-10-01 CL CL2013002829A patent/CL2013002829A1/es unknown
-
2014
- 2014-09-30 CN CN201480060545.XA patent/CN105745323B/zh active Active
- 2014-09-30 BR BR112016006989-7A patent/BR112016006989B1/pt active IP Right Grant
- 2014-09-30 EP EP14850538.1A patent/EP3054013B1/en active Active
- 2014-09-30 GB GB1605054.4A patent/GB2532699B/en active Active
- 2014-09-30 MX MX2016003783A patent/MX2016003783A/es active IP Right Grant
- 2014-09-30 US US15/025,976 patent/US9999663B2/en active Active
- 2014-09-30 CA CA2925369A patent/CA2925369C/en active Active
- 2014-09-30 ES ES14850538T patent/ES2853355T3/es active Active
- 2014-09-30 KR KR1020167011372A patent/KR101822836B1/ko active IP Right Grant
- 2014-09-30 DE DE112014004530.6T patent/DE112014004530T5/de not_active Withdrawn
- 2014-09-30 RU RU2016111978A patent/RU2665848C2/ru active
- 2014-09-30 WO PCT/IB2014/064963 patent/WO2015049633A1/es active Application Filing
- 2014-09-30 PE PE2016000407A patent/PE20160536A1/es unknown
- 2014-10-01 UY UY0001035765A patent/UY35765A/es active IP Right Grant
- 2014-10-01 AR ARP140103655A patent/AR097881A1/es unknown
-
2016
- 2016-03-31 ZA ZA2016/02148A patent/ZA201602148B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2393468T3 (es) * | 2001-01-19 | 2012-12-21 | Vironovative B.V. | Un virus que provoca enfermedad de las vías respiratorias en mamíferos susceptibles |
WO2007120120A2 (en) * | 2005-01-12 | 2007-10-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human parainfluenza virus, methods and uses thereof |
WO2008137981A1 (en) * | 2007-05-08 | 2008-11-13 | Us Government As Represented By The Secy Of The Department Of Health And Human Services | Human parainfluenza viruses having separated p and c genes |
Non-Patent Citations (12)
Title |
---|
BIACCHESI, S.; PHAM, Q. N.; SKIADOPOULOS, M. H.; MURPHY, B. R.; COLLINS, P. L.; BUCHHOLZ, U. J.: "Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates", J VIRO1, vol. 79, 2005, pages 12608 - 12613 |
CSEKE, G.; WRIGHT, D. W.; TOLLEFSON, S. J.; JOHNSON, J. E.; CROWE, J. E., JR.; WILLIAMS, J. V.: "Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats", J VIROL, vol. 81, 2007, pages 698 - 707, XP002604579, DOI: doi:10.1128/JVI.00844-06 |
DENIS, F.; ALAIN, S.; HANTZ, S.; LAGRANGE, P.: "Antiviral vaccination and respiratory mucosal immunity: still disappointing results from a seductive idea", PRESSE MED, vol. 34, 2005, pages 1245 - 1253 |
HAMELIN, M. E.; COUTURE, C.; SACKETT, M.; KIENER, P.; SUZICH, J.; ULBRANDT, N.; BOIVIN, G.: "The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice", ANTIVIR THER, vol. 13, 2008, pages 39 - 46 |
HERFST, S.; DE GRAAF, M.; SCHRAUWEN, E. J.; SPRONG, L.; HUSSAIN, K.; VAN DEN HOOGEN, B. G.; OSTERHAUS, A. D.; FOUCHIER, R. A.: "Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters", J GEN VIROL, vol. 89, 2008, pages 1553 - 1562 |
HERFST, S.; SCHRAUWEN, E. J.; DE GRAAF, M.; VAN AMERONGEN, G.; VAN DEN HOOGEN, B. G.; DE SWART, R. L.; OSTERHAUS, A. D.; FOUCHIER,: "Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques", VACCINE, vol. 26, 2008, pages 4224 - 4230, XP022938971, DOI: doi:10.1016/j.vaccine.2008.05.052 |
KARRON, R. A.; WRIGHT, P. F.; BELSHE, R. B.: "Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants", J INFECT DIS, vol. 191, 2005, pages 1093 - 1104, XP002631431 |
KOLLI, D.; BATAKI, E. L.; SPETCH, L.; GUERRERO-PLATA, A.; JEWELL, A. M.; PIEDRA, P. A.; MILLIGAN, G. N.; GAROFALO, R. P.; CASOLA,: "T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection", J VIROL, vol. 82, 2008, pages 8560 - 8569 |
PHAM QN ET AL.: "Chimeric Recombinant Human Metapneumoviruses with the Nucleoprotein or Phosphoprotein Open Reading Frame Replaced by That of Avian Metapneumovirus Exhibit Improved Growth In Vitro and Attenuation In Vivo.", JOURNAL OF VIROLOGY., vol. 79, no. 24, 2005, pages 15114 - 15122, XP055273516 * |
See also references of EP3054013A4 |
STOVER, C. K.; DE LA CRUZ, V. F.; FUERST, T. R.: "New use of BCG for recombinant vaccines", NATURE, vol. 351, 1991, pages 456 - 460, XP002562555, DOI: doi:10.1038/351456a0 |
YIM, K. C.; CRAGIN, R. P.; BOUKHVALOVA, M. S.; BLANCO, J. C.; HAMLIN, M. E.; BOIVIN, G.; PORTER, D. D.; PRINCE, G. A.: "Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged", VACCINE, vol. 25, 2007, pages 5034 - 5040, XP022110663 |
Also Published As
Publication number | Publication date |
---|---|
MX2016003783A (es) | 2017-01-20 |
UY35765A (es) | 2015-04-30 |
EP3054013B1 (en) | 2020-11-11 |
US9999663B2 (en) | 2018-06-19 |
US20160220662A1 (en) | 2016-08-04 |
DE112014004530T5 (de) | 2016-10-06 |
BR112016006989B1 (pt) | 2023-10-17 |
EP3054013A1 (en) | 2016-08-10 |
KR101822836B1 (ko) | 2018-01-29 |
GB201605054D0 (en) | 2016-05-11 |
RU2016111978A (ru) | 2017-11-10 |
PE20160536A1 (es) | 2016-06-05 |
GB2532699B (en) | 2020-05-13 |
CA2925369A1 (en) | 2015-04-09 |
ZA201602148B (en) | 2017-06-28 |
ES2853355T3 (es) | 2021-09-15 |
CN105745323A (zh) | 2016-07-06 |
EP3054013A4 (en) | 2016-08-31 |
CL2013002829A1 (es) | 2014-04-04 |
RU2665848C2 (ru) | 2018-09-04 |
BR112016006989A2 (pt) | 2017-09-19 |
CA2925369C (en) | 2020-09-22 |
AR097881A1 (es) | 2016-04-20 |
GB2532699A (en) | 2016-05-25 |
KR20160058185A (ko) | 2016-05-24 |
CN105745323B (zh) | 2020-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Graham et al. | Immune-mediated disease pathogenesis in respiratory syncytial virus infection | |
Asensio et al. | Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate | |
US8772256B2 (en) | Codon modified immunogenic compositions and methods of use | |
Durbin et al. | Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines | |
ES2528197T3 (es) | Formulación inmunogénica | |
Rossey et al. | Vaccines against human respiratory syncytial virus in clinical trials, where are we now? | |
Yang et al. | Mucosal vaccines against respiratory syncytial virus | |
Beugeling et al. | Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly | |
Esposito et al. | Respiratory syncytial virus vaccines: an update on those in the immediate pipeline | |
ES2853355T3 (es) | Formulación inmunogénica que contiene BCG vivas recombinantes que expresan antígenos de Metapneumovirus (hMPV), en una suspensión que se prepara a partir de un liofilizado sin la necesidad de adyuvante, apta para su uso farmacéutico | |
Lee et al. | A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus | |
Jorquera et al. | Advances in and the potential of vaccines for respiratory syncytial virus | |
EP4082566A1 (en) | New use of bcg immunogenic formulation expressing a respiratory syncitial virus protein against hmpv | |
Young et al. | Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin | |
BR102020026607A2 (pt) | Formulação imunogênica e usos da formulação imunogênica | |
Céspedes et al. | New Insights for the Rational Design of Human Respiratory Syncytial Virus Vaccines: From Molecular Biology to Clinical Trials | |
Reina et al. | Current situation and future perspectives of vaccines against respiratory syncytial virus | |
Hwang | Efficacy and Safety of Virus Like Particle Vaccines against Respiratory Syncytial Virus in Mouse and Cotton Rat Models | |
Protective | Immunization with a Recombinant Bacillus | |
Cyr | Novel intranasal proteosome-based respiratory syncytial virus (RSV) vaccines elicit protection in mice without the risk of enhanced pathology or eosinophila by triggering innate immune pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14850538 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000407-2016 Country of ref document: PE Ref document number: MX/A/2016/003783 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2925369 Country of ref document: CA Ref document number: 201605054 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20140930 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15025976 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014850538 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014850538 Country of ref document: EP Ref document number: 1120140045306 Country of ref document: DE Ref document number: 112014004530 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16087360 Country of ref document: CO |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016006989 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20167011372 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016111978 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016006989 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160330 |